KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Other Non Operating Income (2019 - 2023)

Aquestive Therapeutics has reported Other Non Operating Income over the past 3 years, most recently at -$1.0 million for Q4 2023.

  • For Q4 2023, Other Non Operating Income changed N/A year-over-year to -$1.0 million; the TTM value through Sep 2024 reached -$1.0 million, down 191.5%, while the annual FY2023 figure was -$1.4 million, N/A changed from the prior year.
  • Other Non Operating Income for Q4 2023 was -$1.0 million at Aquestive Therapeutics, down from -$353000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $13.8 million in Q4 2021 and troughed at -$4.9 million in Q3 2019.
  • A 3-year average of $1.9 million and a median of -$691000.0 in 2023 define the central range for Other Non Operating Income.